Marketdash
Back to News

Evommune's Skin Disorder Drug Could Hit $5 Billion in Peak Sales, Analyst Says

MarketDash Editorial Team
6 days ago
William Blair launches coverage of Evommune with an Outperform rating, projecting blockbuster potential for EVO756 based on promising trial results in chronic urticaria and atopic dermatitis.

Evommune Inc. (EVMN) just got some serious Wall Street attention, and the numbers are eye-popping. William Blair initiated coverage on the biotech with an Outperform rating, highlighting what they're calling a "blockbuster commercial opportunity" for the company's lead drug candidate.

The star of the show is EVO756, a first-in-class MRGPRX2 inhibitor targeting chronic urticaria—basically, severe hives that won't quit. The firm sees strong early clinical data and a market hungry for a safe, effective oral therapy that actually works.

Evommune went public in November with a 10.8 million-share IPO priced at $16, and the early results are backing up the hype. Earlier this year, Phase 2 data in chronic inducible urticaria showed a 30% complete response rate after just four weeks of treatment. Half of those responders tested IgE-high, suggesting the drug works across different patient profiles. Even better, 41% of participants achieved at least a 2-point reduction in itch scores—a clinically meaningful improvement when you're dealing with constant, maddening itching.

But urticaria is just the opening act. The company launched a Phase 2b trial in atopic dermatitis back in August, with topline results expected in the second half of 2026. Analyst Matt Phipps wrote that hitting a 25% or higher complete response rate with good safety would give EVO756 a differentiated profile in chronic spontaneous urticaria, especially since recent approvals like Rhapsido and Dupixent still leave room for oral alternatives.

The market need is real. Phipps emphasizes there's significant unmet demand for an effective, well-tolerated oral option that doctors can prescribe widely without worrying about safety red flags.

William Blair is betting big, estimating peak sales of $5 billion for EVO756 across urticaria and atopic dermatitis. Their risk-adjusted net present value comes to $1.1 billion, or $34 per share. Phipps also noted that oral autoimmune therapies with favorable safety profiles remain attractive acquisition targets—a not-so-subtle hint that Evommune could draw suitor interest down the road.

Price Action: EVMN stock traded up 2.9% at $21.31 on Monday.

Back to News

Evommune's Skin Disorder Drug Could Hit $5 Billion in Peak Sales, Analyst Says

MarketDash Editorial Team
6 days ago
William Blair launches coverage of Evommune with an Outperform rating, projecting blockbuster potential for EVO756 based on promising trial results in chronic urticaria and atopic dermatitis.

Evommune Inc. (EVMN) just got some serious Wall Street attention, and the numbers are eye-popping. William Blair initiated coverage on the biotech with an Outperform rating, highlighting what they're calling a "blockbuster commercial opportunity" for the company's lead drug candidate.

The star of the show is EVO756, a first-in-class MRGPRX2 inhibitor targeting chronic urticaria—basically, severe hives that won't quit. The firm sees strong early clinical data and a market hungry for a safe, effective oral therapy that actually works.

Evommune went public in November with a 10.8 million-share IPO priced at $16, and the early results are backing up the hype. Earlier this year, Phase 2 data in chronic inducible urticaria showed a 30% complete response rate after just four weeks of treatment. Half of those responders tested IgE-high, suggesting the drug works across different patient profiles. Even better, 41% of participants achieved at least a 2-point reduction in itch scores—a clinically meaningful improvement when you're dealing with constant, maddening itching.

But urticaria is just the opening act. The company launched a Phase 2b trial in atopic dermatitis back in August, with topline results expected in the second half of 2026. Analyst Matt Phipps wrote that hitting a 25% or higher complete response rate with good safety would give EVO756 a differentiated profile in chronic spontaneous urticaria, especially since recent approvals like Rhapsido and Dupixent still leave room for oral alternatives.

The market need is real. Phipps emphasizes there's significant unmet demand for an effective, well-tolerated oral option that doctors can prescribe widely without worrying about safety red flags.

William Blair is betting big, estimating peak sales of $5 billion for EVO756 across urticaria and atopic dermatitis. Their risk-adjusted net present value comes to $1.1 billion, or $34 per share. Phipps also noted that oral autoimmune therapies with favorable safety profiles remain attractive acquisition targets—a not-so-subtle hint that Evommune could draw suitor interest down the road.

Price Action: EVMN stock traded up 2.9% at $21.31 on Monday.